MARMORINO, FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 315
EU - Europa 250
AS - Asia 61
SA - Sud America 18
AF - Africa 10
Totale 654
Nazione #
US - Stati Uniti d'America 311
IT - Italia 142
DE - Germania 52
FR - Francia 20
IN - India 16
BR - Brasile 10
PS - Palestinian Territory 10
JP - Giappone 8
GB - Regno Unito 6
KR - Corea 6
RO - Romania 6
SG - Singapore 6
CA - Canada 4
CN - Cina 4
CL - Cile 3
CO - Colombia 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
ES - Italia 3
FI - Finlandia 3
ID - Indonesia 3
PL - Polonia 3
SE - Svezia 3
UG - Uganda 3
ZA - Sudafrica 3
CH - Svizzera 2
EC - Ecuador 2
IL - Israele 2
NL - Olanda 2
PK - Pakistan 2
RU - Federazione Russa 2
CD - Congo 1
CY - Cipro 1
HK - Hong Kong 1
MY - Malesia 1
PT - Portogallo 1
SI - Slovenia 1
UA - Ucraina 1
VN - Vietnam 1
Totale 654
Città #
Ashburn 33
Fairfield 24
Seattle 24
Woodbridge 22
Buffalo 21
Santa Cruz 18
Rome 13
Cambridge 12
Milan 12
Wilmington 12
Houston 10
Nürnberg 8
Serra 8
Pisa 7
Los Angeles 6
Chicago 5
Genoa 5
Herndon 5
Ann Arbor 4
Carife 4
Las Vegas 4
Mountain View 4
Okayama 4
Bethesda 3
Chennai 3
Des Moines 3
Fortaleza 3
Helsinki 3
Muizenberg 3
Mumbai 3
Nardò 3
New York 3
Palermo 3
Peccioli 3
Phoenix 3
Stockholm 3
Araraquara 2
Bandung 2
Beijing 2
Berlin 2
Boardman 2
Boydton 2
Bremen 2
Brno 2
Busto Arsizio 2
Cheyenne 2
Cinisello Balsamo 2
Clearwater 2
Corpus Christi 2
Deiva Marina 2
Gáldar 2
Hacienda Ibarra 2
Henderson 2
Iasi 2
Kanata 2
Lahore 2
Leawood 2
Montefalco 2
Paris 2
Płońsk 2
Riva 2
Sanluri 2
Seodaemun-gu 2
Tel Aviv 2
Trieste 2
Verona 2
Vicopisano 2
Wonju 2
Alassio 1
Amsterdam 1
Arani 1
Ariano Irpino 1
Asahikawa 1
Atlanta 1
Augusta 1
Bari 1
Barsinghausen 1
Bergamo 1
Bogotá 1
Brasília 1
Brindisi 1
Béjaïa 1
Campina Grande 1
Casciago 1
Castelpoto 1
Catania 1
Chandler 1
Costa Mesa 1
Council Bluffs 1
Crugers 1
Dallas 1
Esslingen am Neckar 1
Faro 1
Fleming Island 1
Flensburg 1
Frankfurt Am Main 1
Genova 1
Gorgonzola 1
Hanoi 1
Hyderabad 1
Totale 400
Nome #
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer, file e0d6c92c-198b-fcf8-e053-d805fe0aa794 195
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis, file e0d6c928-e9a1-fcf8-e053-d805fe0aa794 165
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients, file cdf57598-8019-4462-b288-0dc483ec9964 131
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group, file e0d6c92c-363a-fcf8-e053-d805fe0aa794 105
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies, file e0d6c931-b004-fcf8-e053-d805fe0aa794 26
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer, file e0d6c92a-065f-fcf8-e053-d805fe0aa794 11
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials, file 198caa20-17dc-4428-a4ee-95bf6b386924 7
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrences, file 72d08092-5981-48a6-8f33-c0ba31fda067 5
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO, file e0d6c931-4105-fcf8-e053-d805fe0aa794 5
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO, file 4870a7f6-1976-4e48-9a88-2922c6ef7a46 4
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer, file e0d6c92f-d335-fcf8-e053-d805fe0aa794 3
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies, file e0d6c930-f2c0-fcf8-e053-d805fe0aa794 3
Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application, file b2a4d8ef-07e5-4fed-9fa6-c8b714ac6873 2
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study, file e0d6c92c-0d56-fcf8-e053-d805fe0aa794 2
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope, file e0d6c92c-3dbf-fcf8-e053-d805fe0aa794 2
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial, file e0d6c92d-077c-fcf8-e053-d805fe0aa794 2
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials, file e0d6c92f-8490-fcf8-e053-d805fe0aa794 2
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge, file e0d6c92f-d87f-fcf8-e053-d805fe0aa794 2
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO, file e0d6c930-b26c-fcf8-e053-d805fe0aa794 2
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer, file e0d6c930-c440-fcf8-e053-d805fe0aa794 2
Totale 676
Categoria #
all - tutte 1.433
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.433


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 5 7 13
2019/2020117 5 3 3 5 16 17 13 13 16 8 8 10
2020/2021126 19 21 8 5 11 13 7 8 10 10 8 6
2021/202290 3 8 5 4 11 6 3 6 7 5 25 7
2022/2023146 8 4 21 21 18 13 6 16 4 2 23 10
2023/2024152 6 11 19 16 28 16 19 20 8 9 0 0
Totale 676